At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ERAS Erasca, Inc.
Not Yet Opened 06-24 16:00:00 EDT
2.16
+0.05
+2.37%
盘后2.16
+0.000.00%
19:02 EDT
High2.19
Low2.09
Vol3.00M
Open2.12
D1 Closing2.11
Amplitude4.74%
Mkt Cap588.75M
Tradable Cap250.56M
Total Shares272.57M
T/O6.43M
T/O Rate2.59%
Tradable Shares116.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
BRIEF-Erasca Initiates Seacraft-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib In Patients With Nras-Mutant Melanoma
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.